Science 37 (SNCE) is an American clinical research company that specializes in Decentralized Clinical Trials. CEO David Coman weighs in on the stock beginning to trade today on the Nasdaq after a SPAC deal with LifeSci Acquisition II Corp. Approximately $235M net cash was received in the deal. How will the stock continue to perform and what is next for the now public company?
07 Oct 2021
The Watch List
28 Apr 2022
The Watch List
20 Apr 2022
Next Gen Investing
27 Jun 2022
Trading 360
23 Jun 2022
The Watch List
13 May 2022
Trading 360
31 Mar 2022